Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 1
2012 1
2014 1
2015 2
2017 2
2019 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Sanz MA, et al. Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Blood. 2019. PMID: 30803991 Free PMC article. Review.
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder …
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review c …
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Sanz MA, et al. Blood. 2009 Feb 26;113(9):1875-91. doi: 10.1182/blood-2008-04-150250. Epub 2008 Sep 23. Blood. 2009. PMID: 18812465 Free article. Review.
Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL …
Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review c …
Risk/benefit profile of arsenic trioxide.
Rust DM, Soignet SL. Rust DM, et al. Oncologist. 2001;6 Suppl 2:29-32. doi: 10.1634/theoncologist.6-suppl_2-29. Oncologist. 2001. PMID: 11331438 Free article. Review.
In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the positive safety and efficacy outcomes of a smaller 12-patient pilot study. Common adverse events were hyperleukocytosis, APL differentia …
In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the positi …
The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
Mohammadzadeh Z, Omidkhoda A, Chahardouli B, Hoseinzadeh G, Moghaddam KA, Mousavi SA, Rostami S. Mohammadzadeh Z, et al. BMC Cancer. 2021 Jan 9;21(1):46. doi: 10.1186/s12885-021-07783-y. BMC Cancer. 2021. PMID: 33422029 Free PMC article.
BACKGROUND: Although arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are well-tolerated and effective treatments for Acute Promyelocytic Leukemia (APL), Differentiation Syndrome (DS) is a lethal side effect in some patients. ...
BACKGROUND: Although arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are well-tolerated and effective treatments for Acute Promyel …
Treatment of acute promyelocytic leukemia by retinoids.
Fenaux P, Wang ZZ, Degos L. Fenaux P, et al. Curr Top Microbiol Immunol. 2007;313:101-28. doi: 10.1007/978-3-540-34594-7_7. Curr Top Microbiol Immunol. 2007. PMID: 17217041 Review.
In those patients, addition of arsenic derivatives to induction or consolidation treatment (or both treatments together) may prove useful and is currently being tested. ATRA syndrome (now generally called APL differentiation syndrome, as it is also seen with …
In those patients, addition of arsenic derivatives to induction or consolidation treatment (or both treatments together) may prove useful an …
ATRA treatment slowed P-selectin-mediated rolling of flowing HL60 cells in a mechano-chemical-dependent manner.
Dong X, Peng S, Ling Y, Huang B, Tu W, Sun X, Li Q, Fang Y, Wu J. Dong X, et al. Front Immunol. 2023 Apr 24;14:1148543. doi: 10.3389/fimmu.2023.1148543. eCollection 2023. Front Immunol. 2023. PMID: 37168856 Free PMC article.
All-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) toward granulocytes may trigger APL differentiation syndrome (DS), but there is less knowledge about the mechano-chemical regulation mechanism of APL DS under the mec …
All-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) toward granulocytes may trigger APL d …
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MA. Tallman M, et al. Clin Lymphoma Myeloma Leuk. 2010 Oct;10 Suppl 3:S122-6. doi: 10.3816/CLML.2010.s.023. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21115429
Cure in APL is also largely dependent on timely and effective supportive care measures that counteract such life-threatening emergencies as coagulopathy and APL differentiation syndrome. The risk of mortality during induction and the risk of relapse following …
Cure in APL is also largely dependent on timely and effective supportive care measures that counteract such life-threatening emergencies as …
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K, Shariftabrizi A, Tavangar SM, Sanaat Z, Rostami S, Jahani M, Ghavamzadeh A. Alimoghaddam K, et al. Leuk Lymphoma. 2006 Jan;47(1):81-8. doi: 10.1080/10428190500300373. Leuk Lymphoma. 2006. PMID: 16321832 Clinical Trial.
Main toxicities included hyper-leukocytosis, hepatic toxicity and APL differentiation syndrome. The results imply that arsenic trioxide is an effective anti-leukemia and anti-angiogenesis agent in new cases of APL....
Main toxicities included hyper-leukocytosis, hepatic toxicity and APL differentiation syndrome. The results imply that …
Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M. Ghavamzadeh A, et al. J Clin Oncol. 2011 Jul 10;29(20):2753-7. doi: 10.1200/JCO.2010.32.2107. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646615 Clinical Trial.
The most common cause of remission failure was early death owing to APL differentiation syndrome (13.2%). The most important prognostic factor for early mortality was a high WBC count at presentation. ...
The most common cause of remission failure was early death owing to APL differentiation syndrome (13.2%). The most impo …
15 results